Christian Friedrich Hense
Chief Operating Officer at Universal Diagnostics SA
Profile
Christian Friedrich Hense currently works as the Chief Operating Officer & Director at Universal Diagnostics SA.
Christian Friedrich Hense active positions
Companies | Position | Start |
---|---|---|
Universal Diagnostics SA
Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Chief Operating Officer | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Universal Diagnostics SA
Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Electronic Technology |
- Stock Market
- Insiders
- Christian Friedrich Hense